The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

Lost and Looking for guidance PLEASE

Forums General Melanoma Community Lost and Looking for guidance PLEASE

  • Post
    Linda/Kentucky
    Participant

    Hello everyone

    Hello everyone

    My husband stage IV with "innumerable" mets to liver and lung as well as some other areas of his body are again, like so many of you, in limbo what treatment to do next.  We have an appointment Thurs. with our oncologist at Vandy to give us some guidance and advice.  This is a short rundown so far.  Nov. 09 diagnosed with melanoma behind right ear.  Sent to Vandy was scheduled for radical neck but cancelled following scans showing mets to bilateral femurs.  Took 2 rounds of high dose IL-2.  Results were increased mets to lung and liver.  Sent to Knox. Tenn. for Ipi compassionate trial in April.  Had kind of a tough time throughout that with lots of fatigue and aches.  Scans at 12 weeks showed no new mets but increased size of mets.  So goes the "12 week waiting period"  Scan results on Oct. 6th showed strong progression everywhere.  So far he has been lucky (blessed) no brain mets especially since original spot was behind ear on mastoid bone.  So here we are now back to square one and nothing up to this point has even began to stop this ugly beast……It is so discouraging to keep hearing bad news EVERYTIME we go to the Dr. 

    Anybody with ANY ideas?  I have researched till my brain is fried.  Were kind of looking at the Novalis radiation which can be used on lungs & liver but…. he may have tooo many mets to that area,  We also thought about some type of chemo along with this.  I would REALLY like to be able to do the AntiPD-1 but due to taking Ipi we are disqualified. So anybody who is thinking about Ipi consider (when available) this tx. first.  I have heard Temodar, Taxol/Carboplatin and don't know if he would be candidate for Gleevac? 

    Thanks for any advice or encouragement or paryers or whatever your willing to give……….

     

    Linda/Kentucy

    Loading spinner
Viewing 7 reply threads
  • Replies
      jim Breitfeller
      Participant
       
      A phase 1b, Open-label, Multicenter, multidose, Dose-escalation Study of MDX-1106 in Subjects with Selected Advance or Recurrent Malignancies
      Protocol Number:
      J08113
      Phase:
      Phase I
      Physician:
      Julie Brahmer
      Purpose:
      To assess the safety and tolerability of multiple doses of MDX-1106 in subjects with selected advanced or recurrent malignancies: Metastatic Castration-Resistant Prostate Cancer, Metastatic Melanoma, Non-Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma. It will be given in different doses. We want to find the best dose and see if we can give this studydrug safely. Laboratory research suggests that MDX-1106 may help the immune system to fight cancer. In this study, the safety of MDX-1106 given in multiple doses(how well people tolerate it) and its effect on your cancer and immune system will be looked at. MDX-1106 is the study drug that is being tested. It is an antibody against a molecule called PD 1. The PD-1 molecule is important because it helps control the activity of the immune system by slowing down immune responses. When your immune system is trying to fight your cancer, slowing it down may n ot be good. Blocking PD-1 may help your immune system do a better job of fighting your cancer
      Eligibility:
      – recurent or refractory cancers, including non-small cell lung cancer, malignant melanoma, renal (clear) cell carcinoma, or metastatic catration-resistant prostate adenocarcinoma – prior treatment completed at least 4 weeks before study drug is given – good physical condition – good blood counts – no active autoimmune disease – no active infection – no steroid use
      Treatment:
      The study drug will be given to you as an intravenous (IV) infusion. This means it will be given as an injection into a vein. It will last for about an hour. It may cause some pain. The infusion will be given every 14 days for a total of 4 infusions in each cycle and up to 12 cycles may be given. Participants will be required to remain in clinic for up to 1 hour after the completion of the infusion. The expected maximum duration of study drug treatment for a participant is approximately 2 years. The expected maximum duration for a participant is 3 years.
      Population:
      Adult
      Last Update
      10/18/2010 04:02 AM
      Loading spinner
        LynnLuc
        Participant

        Maybe he can get into this trial…I am currently on this exact trial except I am NED . It is offered to those who are NED and is also offered in a separate trial for thos who are not. (.MDX-1106  is now called BMS-936558 because Bristol Myers Squibb bought it from Medarex)…

        Phase I Pilot Study of Peptide Vaccine Comprising gp100:209-217(210M), MART-1:26-35(27L), gp100:280-288(288V), and NY-ESO-1 Emulsified in Montanide ISA 51 VG and Anti-PD-1 Human Monoclonal Antibody MDX-1106 in Patients With Unresectable Stage III or IV Melanoma

        Alternate Title
        Basic Trial Information
        Objectives
        Entry Criteria
        Expected Enrollment
        Outcomes
        Outline
        Trial Contact Information
        Registry Information

        Alternate Title

        Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

         

        Basic Trial Information

         

         

        Phase Type Status Age Sponsor Protocol IDs
        Phase I Biomarker/Laboratory analysis, Treatment Active 16 and over NCI MCC-15400
        MCC-15400, 7997, NCT01176461

        Objectives

         

        Primary

        1. To assess the safety and tolerability of multiple class I peptide vaccine comprising gp100:209-217(210M), MART-1:26-35(27L), gp100:280-288(288V), and NY-ESO-1 emulsified in Montanide ISA 51 VG and anti-PD-1 human monoclonal antibody MDX-1106 (BMS-936558) in HLA-A*0201-positive patients with unresectable stage III or IV malignant melanoma.

         

        Secondary

        1. To evaluate the immune response at week 12 in patients treated with these regimens compared to the immune response to peptide vaccine alone that was determined in previous studies.
        2. To assess the host immune response (immunogenicity) to BMS-936558.
        3. To assess, preliminarily, the efficacy of these regimens in these patients.

         

        Entry Criteria

        Disease Characteristics:

         

        • Histologically confirmed melanoma
          • Unresectable stage III or IV disease
          • HLA-A*0201 positive by DNA allele-specific PCR assay

           

        • Positive staining of tumor tissue for ≥ 1 of the following: antibody HMB-45 for gp100, NY-ESO-1, and/or MART-1

           

        • At least 1 measurable lesion

           

        • Must have failed ≥ 1 chemotherapy regimen for metastatic disease

           

        • Prior treated brain and meningeal metastases allowed provided the following criteria are met:
          • No evidence of progression by MRI within the past 8 weeks
          • Off immunosuppressive doses of systemic steroids (> 10 mg/day prednisone or equivalent) for ≥ 2 weeks

           

        • Prior/Concurrent Therapy:

         

        • See Disease Characteristics
        • May have received ≤ 2 prior chemotherapy regimens
        • At least 4 weeks since prior chemotherapy or immunotherapy (tumor vaccine, cytokine, or growth factor given to control the cancer) and recovered
        • At least 2 weeks since prior immunosuppressive doses of systemic medications, such as steroids or absorbed topical steroids (> 10 mg/day prednisone or equivalent)
        • At least 4 weeks since prior systemic radiotherapy
          • At least 2 weeks since prior focal radiotherapy
          • More than 8 weeks since prior radiopharmaceuticals (strontium, samarium)
        • At least 6 weeks since prior nitrosourea
        • At least 2 weeks since prior surgery that required general anesthesia
          • At least 72 hours since prior surgery requiring local and/or epidural anesthesia
        • No prior anti-PD-1, anti-PD-L1, anti-PDL-2, or anti-CTLA-4 antibody (or any other antibody targeting T-cell costimulation pathways)
        • No concurrent participation in another clinical study involving treatment with medications, radiotherapy, or surgery or prior participation in this study
        • No concurrent use of any of the following:
          • Other anticancer agents
          • Immunosuppressive agents
          • Immunosuppressive doses of systemic or topical steroids whose absorption is expected to result in systemically immunosuppressive steroid levels
          • Non-oncologic vaccines (during and ≥ 4 weeks after study treatment)

         

         

        Patient Characteristics:

         

        • ECOG performance status 0-1
        • Life expectancy ≥ 3 months
        • WBC ≥ 2,000/μL
        • ANC ≥ 1,500/μL
        • Platelet count ≥ 100,000/μL
        • Hemoglobin ≥ 9.0 g/dL
        • Serum creatinine ≤ 2 mg/dL
        • AST and/or ALT ≤ 2.5 times upper limit of normal (ULN) (≤ 5 times ULN for hepatic metastasis)
        • Bilirubin ≤ 2 times ULN (< 3 times ULN for patients with Gilbert syndrome)
        • Fertile patients must agree to use effective contraception for ≥ 28 days before, during, and for ≥ 70 days (180 days for males) after completion of treatment period
        • Negative pregnancy test
        • Not pregnant or nursing
        • Willing to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocol
        • No history of severe hypersensitivity reactions to other monoclonal antibodies
        • No systemic hypersensitivity to Montanide ISA 51 VG or any vaccine component
        • No active malignancy within the past 2 years except for curatively treated local cancer, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast
        • No prior or active autoimmune disease, or history of syndrome requiring systemic steroids or immunosuppressive medications
          • Patients with vitiligo or resolved childhood asthma and/or atopy allowed
        • No known HIV positivity or AIDS
        • Not positive for hepatitis B virus surface antigen or hepatitis C virus RNA indicating active or chronic infection
        • No underlying medical condition (e.g., a condition associated with diarrhea) that, in the investigator's opinion, would make the administration of any of the study drugs hazardous to the patient, or obscure the interpretation of toxicity determination or adverse events
        • No concurrent medical condition requiring the use of immunosuppressive doses of systemic or absorbable topical corticosteroids

         

         

         

        Expected Enrollment

        30

        Outcomes

        Primary Outcome(s)

        Best overall response (complete or partial response, stable disease, or progressive disease)
        Adverse events

        Secondary Outcome(s)

        Time to response
        Duration of response

         

        Outline

         

        This is a dose-escalation study of anti-PD-1 human monoclonal antibody MDX-1106.

         

        Patients receive peptide vaccines comprising gp 100 (210M), MART-1 (27L), gp100 (288V), and NY-ESO-1(165V) emulsified by Montanide ISA 51 VG subcutaneously and anti-PD-1 human monoclonal antibody MDX-1106 IV over 60 minutes once a week on weeks 1, 3, 5, 7, 9, and 11. Treatment repeats every 12 weeks for 2 courses. Patients with responsive or stable disease continue to receive anti-PD-1 human monoclonal antibody MDX-1106 IV over 60 minutes every 12 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.

        Blood samples are collected for pharmacokinetic and immunologic analysis.

        After completion of study therapy, patients are followed up periodically for 2 years.

        Trial Contact Information

        Trial Lead Organizations

        H. Lee Moffitt Cancer Center and Research Institute at University of South Florida

         

         

        Jeffrey Weber, MD, PhD, Principal investigator
        Ph: 813-747-2691; 888-663-3488

         

        Trial Sites

         

         

        U.S.A.
        Florida
          Tampa
               
         
         
         
          H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
         
          Clinical Trials Office – H. Lee Moffitt Cancer Center and Reseach Institute
        Ph:  800-456-7121
           
          Email: [email protected]
        Loading spinner
        LynnLuc
        Participant

        Maybe he can get into this trial…I am currently on this exact trial except I am NED . It is offered to those who are NED and is also offered in a separate trial for thos who are not. (.MDX-1106  is now called BMS-936558 because Bristol Myers Squibb bought it from Medarex)…

        Phase I Pilot Study of Peptide Vaccine Comprising gp100:209-217(210M), MART-1:26-35(27L), gp100:280-288(288V), and NY-ESO-1 Emulsified in Montanide ISA 51 VG and Anti-PD-1 Human Monoclonal Antibody MDX-1106 in Patients With Unresectable Stage III or IV Melanoma

        Alternate Title
        Basic Trial Information
        Objectives
        Entry Criteria
        Expected Enrollment
        Outcomes
        Outline
        Trial Contact Information
        Registry Information

        Alternate Title

        Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

         

        Basic Trial Information

         

         

        Phase Type Status Age Sponsor Protocol IDs
        Phase I Biomarker/Laboratory analysis, Treatment Active 16 and over NCI MCC-15400
        MCC-15400, 7997, NCT01176461

        Objectives

         

        Primary

        1. To assess the safety and tolerability of multiple class I peptide vaccine comprising gp100:209-217(210M), MART-1:26-35(27L), gp100:280-288(288V), and NY-ESO-1 emulsified in Montanide ISA 51 VG and anti-PD-1 human monoclonal antibody MDX-1106 (BMS-936558) in HLA-A*0201-positive patients with unresectable stage III or IV malignant melanoma.

         

        Secondary

        1. To evaluate the immune response at week 12 in patients treated with these regimens compared to the immune response to peptide vaccine alone that was determined in previous studies.
        2. To assess the host immune response (immunogenicity) to BMS-936558.
        3. To assess, preliminarily, the efficacy of these regimens in these patients.

         

        Entry Criteria

        Disease Characteristics:

         

        • Histologically confirmed melanoma
          • Unresectable stage III or IV disease
          • HLA-A*0201 positive by DNA allele-specific PCR assay

           

        • Positive staining of tumor tissue for ≥ 1 of the following: antibody HMB-45 for gp100, NY-ESO-1, and/or MART-1

           

        • At least 1 measurable lesion

           

        • Must have failed ≥ 1 chemotherapy regimen for metastatic disease

           

        • Prior treated brain and meningeal metastases allowed provided the following criteria are met:
          • No evidence of progression by MRI within the past 8 weeks
          • Off immunosuppressive doses of systemic steroids (> 10 mg/day prednisone or equivalent) for ≥ 2 weeks

           

        • Prior/Concurrent Therapy:

         

        • See Disease Characteristics
        • May have received ≤ 2 prior chemotherapy regimens
        • At least 4 weeks since prior chemotherapy or immunotherapy (tumor vaccine, cytokine, or growth factor given to control the cancer) and recovered
        • At least 2 weeks since prior immunosuppressive doses of systemic medications, such as steroids or absorbed topical steroids (> 10 mg/day prednisone or equivalent)
        • At least 4 weeks since prior systemic radiotherapy
          • At least 2 weeks since prior focal radiotherapy
          • More than 8 weeks since prior radiopharmaceuticals (strontium, samarium)
        • At least 6 weeks since prior nitrosourea
        • At least 2 weeks since prior surgery that required general anesthesia
          • At least 72 hours since prior surgery requiring local and/or epidural anesthesia
        • No prior anti-PD-1, anti-PD-L1, anti-PDL-2, or anti-CTLA-4 antibody (or any other antibody targeting T-cell costimulation pathways)
        • No concurrent participation in another clinical study involving treatment with medications, radiotherapy, or surgery or prior participation in this study
        • No concurrent use of any of the following:
          • Other anticancer agents
          • Immunosuppressive agents
          • Immunosuppressive doses of systemic or topical steroids whose absorption is expected to result in systemically immunosuppressive steroid levels
          • Non-oncologic vaccines (during and ≥ 4 weeks after study treatment)

         

         

        Patient Characteristics:

         

        • ECOG performance status 0-1
        • Life expectancy ≥ 3 months
        • WBC ≥ 2,000/μL
        • ANC ≥ 1,500/μL
        • Platelet count ≥ 100,000/μL
        • Hemoglobin ≥ 9.0 g/dL
        • Serum creatinine ≤ 2 mg/dL
        • AST and/or ALT ≤ 2.5 times upper limit of normal (ULN) (≤ 5 times ULN for hepatic metastasis)
        • Bilirubin ≤ 2 times ULN (< 3 times ULN for patients with Gilbert syndrome)
        • Fertile patients must agree to use effective contraception for ≥ 28 days before, during, and for ≥ 70 days (180 days for males) after completion of treatment period
        • Negative pregnancy test
        • Not pregnant or nursing
        • Willing to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocol
        • No history of severe hypersensitivity reactions to other monoclonal antibodies
        • No systemic hypersensitivity to Montanide ISA 51 VG or any vaccine component
        • No active malignancy within the past 2 years except for curatively treated local cancer, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast
        • No prior or active autoimmune disease, or history of syndrome requiring systemic steroids or immunosuppressive medications
          • Patients with vitiligo or resolved childhood asthma and/or atopy allowed
        • No known HIV positivity or AIDS
        • Not positive for hepatitis B virus surface antigen or hepatitis C virus RNA indicating active or chronic infection
        • No underlying medical condition (e.g., a condition associated with diarrhea) that, in the investigator's opinion, would make the administration of any of the study drugs hazardous to the patient, or obscure the interpretation of toxicity determination or adverse events
        • No concurrent medical condition requiring the use of immunosuppressive doses of systemic or absorbable topical corticosteroids

         

         

         

        Expected Enrollment

        30

        Outcomes

        Primary Outcome(s)

        Best overall response (complete or partial response, stable disease, or progressive disease)
        Adverse events

        Secondary Outcome(s)

        Time to response
        Duration of response

         

        Outline

         

        This is a dose-escalation study of anti-PD-1 human monoclonal antibody MDX-1106.

         

        Patients receive peptide vaccines comprising gp 100 (210M), MART-1 (27L), gp100 (288V), and NY-ESO-1(165V) emulsified by Montanide ISA 51 VG subcutaneously and anti-PD-1 human monoclonal antibody MDX-1106 IV over 60 minutes once a week on weeks 1, 3, 5, 7, 9, and 11. Treatment repeats every 12 weeks for 2 courses. Patients with responsive or stable disease continue to receive anti-PD-1 human monoclonal antibody MDX-1106 IV over 60 minutes every 12 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.

        Blood samples are collected for pharmacokinetic and immunologic analysis.

        After completion of study therapy, patients are followed up periodically for 2 years.

        Trial Contact Information

        Trial Lead Organizations

        H. Lee Moffitt Cancer Center and Research Institute at University of South Florida

         

         

        Jeffrey Weber, MD, PhD, Principal investigator
        Ph: 813-747-2691; 888-663-3488

         

        Trial Sites

         

         

        U.S.A.
        Florida
          Tampa
               
         
         
         
          H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
         
          Clinical Trials Office – H. Lee Moffitt Cancer Center and Reseach Institute
        Ph:  800-456-7121
           
          Email: [email protected]
        Loading spinner
      jim Breitfeller
      Participant
       
      A phase 1b, Open-label, Multicenter, multidose, Dose-escalation Study of MDX-1106 in Subjects with Selected Advance or Recurrent Malignancies
      Protocol Number:
      J08113
      Phase:
      Phase I
      Physician:
      Julie Brahmer
      Purpose:
      To assess the safety and tolerability of multiple doses of MDX-1106 in subjects with selected advanced or recurrent malignancies: Metastatic Castration-Resistant Prostate Cancer, Metastatic Melanoma, Non-Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma. It will be given in different doses. We want to find the best dose and see if we can give this studydrug safely. Laboratory research suggests that MDX-1106 may help the immune system to fight cancer. In this study, the safety of MDX-1106 given in multiple doses(how well people tolerate it) and its effect on your cancer and immune system will be looked at. MDX-1106 is the study drug that is being tested. It is an antibody against a molecule called PD 1. The PD-1 molecule is important because it helps control the activity of the immune system by slowing down immune responses. When your immune system is trying to fight your cancer, slowing it down may n ot be good. Blocking PD-1 may help your immune system do a better job of fighting your cancer
      Eligibility:
      – recurent or refractory cancers, including non-small cell lung cancer, malignant melanoma, renal (clear) cell carcinoma, or metastatic catration-resistant prostate adenocarcinoma – prior treatment completed at least 4 weeks before study drug is given – good physical condition – good blood counts – no active autoimmune disease – no active infection – no steroid use
      Treatment:
      The study drug will be given to you as an intravenous (IV) infusion. This means it will be given as an injection into a vein. It will last for about an hour. It may cause some pain. The infusion will be given every 14 days for a total of 4 infusions in each cycle and up to 12 cycles may be given. Participants will be required to remain in clinic for up to 1 hour after the completion of the infusion. The expected maximum duration of study drug treatment for a participant is approximately 2 years. The expected maximum duration for a participant is 3 years.
      Population:
      Adult
      Last Update
      10/18/2010 04:02 AM
      Loading spinner
      jim Breitfeller
      Participant
       
      A phase 1b, Open-label, Multicenter, multidose, Dose-escalation Study of MDX-1106 in Subjects with Selected Advance or Recurrent Malignancies
      Protocol Number:
      J08113
      Phase:
      Phase I
      Physician:
      Julie Brahmer
      Purpose:
      To assess the safety and tolerability of multiple doses of MDX-1106 in subjects with selected advanced or recurrent malignancies: Metastatic Castration-Resistant Prostate Cancer, Metastatic Melanoma, Non-Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma. It will be given in different doses. We want to find the best dose and see if we can give this studydrug safely. Laboratory research suggests that MDX-1106 may help the immune system to fight cancer. In this study, the safety of MDX-1106 given in multiple doses(how well people tolerate it) and its effect on your cancer and immune system will be looked at. MDX-1106 is the study drug that is being tested. It is an antibody against a molecule called PD 1. The PD-1 molecule is important because it helps control the activity of the immune system by slowing down immune responses. When your immune system is trying to fight your cancer, slowing it down may n ot be good. Blocking PD-1 may help your immune system do a better job of fighting your cancer
      Eligibility:
      – recurent or refractory cancers, including non-small cell lung cancer, malignant melanoma, renal (clear) cell carcinoma, or metastatic catration-resistant prostate adenocarcinoma – prior treatment completed at least 4 weeks before study drug is given – good physical condition – good blood counts – no active autoimmune disease – no active infection – no steroid use
      Treatment:
      The study drug will be given to you as an intravenous (IV) infusion. This means it will be given as an injection into a vein. It will last for about an hour. It may cause some pain. The infusion will be given every 14 days for a total of 4 infusions in each cycle and up to 12 cycles may be given. Participants will be required to remain in clinic for up to 1 hour after the completion of the infusion. The expected maximum duration of study drug treatment for a participant is approximately 2 years. The expected maximum duration for a participant is 3 years.
      Population:
      Adult
      Last Update
      10/18/2010 04:02 AM
      Loading spinner
      jim Breitfeller
      Participant
       
      A phase 1b, Open-label, Multicenter, multidose, Dose-escalation Study of MDX-1106 in Subjects with Selected Advance or Recurrent Malignancies
      Protocol Number:
      J08113
      Phase:
      Phase I
      Physician:
      Julie Brahmer
      Purpose:
      To assess the safety and tolerability of multiple doses of MDX-1106 in subjects with selected advanced or recurrent malignancies: Metastatic Castration-Resistant Prostate Cancer, Metastatic Melanoma, Non-Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma. It will be given in different doses. We want to find the best dose and see if we can give this studydrug safely. Laboratory research suggests that MDX-1106 may help the immune system to fight cancer. In this study, the safety of MDX-1106 given in multiple doses(how well people tolerate it) and its effect on your cancer and immune system will be looked at. MDX-1106 is the study drug that is being tested. It is an antibody against a molecule called PD 1. The PD-1 molecule is important because it helps control the activity of the immune system by slowing down immune responses. When your immune system is trying to fight your cancer, slowing it down may n ot be good. Blocking PD-1 may help your immune system do a better job of fighting your cancer
      Eligibility:
      – recurent or refractory cancers, including non-small cell lung cancer, malignant melanoma, renal (clear) cell carcinoma, or metastatic catration-resistant prostate adenocarcinoma – prior treatment completed at least 4 weeks before study drug is given – good physical condition – good blood counts – no active autoimmune disease – no active infection – no steroid use
      Treatment:
      The study drug will be given to you as an intravenous (IV) infusion. This means it will be given as an injection into a vein. It will last for about an hour. It may cause some pain. The infusion will be given every 14 days for a total of 4 infusions in each cycle and up to 12 cycles may be given. Participants will be required to remain in clinic for up to 1 hour after the completion of the infusion. The expected maximum duration of study drug treatment for a participant is approximately 2 years. The expected maximum duration for a participant is 3 years.
      Population:
      Adult
      Last Update
      10/18/2010 04:02 AM
      Loading spinner
      Lori C
      Participant

      Linda, Will was on taxol  & carbo and it DID reduce the tumors.  What happened to him was the result, probably, of how frail he had become (6 feet tall, down to about 140 pounds) and part of that was because he'd done the extremely toxic biochemotherapy right before this. 

      He had lung, liver, bone, and spleen mets.  But the taxol and carbo *was* reducing the tumor burden.  He had no brain mets either.  It's an option to consider; I'd make sure that you are getting plenty of nutritional support, etc., if you go this route, though, as there are side effects that can be rough.

      Loading spinner
      Lori C
      Participant

      Linda, Will was on taxol  & carbo and it DID reduce the tumors.  What happened to him was the result, probably, of how frail he had become (6 feet tall, down to about 140 pounds) and part of that was because he'd done the extremely toxic biochemotherapy right before this. 

      He had lung, liver, bone, and spleen mets.  But the taxol and carbo *was* reducing the tumor burden.  He had no brain mets either.  It's an option to consider; I'd make sure that you are getting plenty of nutritional support, etc., if you go this route, though, as there are side effects that can be rough.

      Loading spinner
      SusanE
      Participant

      Hi Linda. Have you tested for Ckit or Braf?

       

      If considering chemo, there is a trial combining Carboplatin, Paclitaxel and Everolimus.

       

      Hang in there. I wish I could offer more.

       

      Susan wife to Jerry Stage III

      Loading spinner
        Linda/Kentucky
        Participant

        He tested negative to the BRAF gene and have not been tested for the C-Kit this is one question I'm going to ask Thurs. at the onc. visit.  I have heard the Taxol/carboplatin may be something to I don't know anything about the Everolimus will do some research on it.  Thanks to all  for the trial info.

        Loading spinner
        Linda/Kentucky
        Participant

        He tested negative to the BRAF gene and have not been tested for the C-Kit this is one question I'm going to ask Thurs. at the onc. visit.  I have heard the Taxol/carboplatin may be something to I don't know anything about the Everolimus will do some research on it.  Thanks to all  for the trial info.

        Loading spinner
      SusanE
      Participant

      Hi Linda. Have you tested for Ckit or Braf?

       

      If considering chemo, there is a trial combining Carboplatin, Paclitaxel and Everolimus.

       

      Hang in there. I wish I could offer more.

       

      Susan wife to Jerry Stage III

      Loading spinner
Viewing 7 reply threads
  • You must be logged in to reply to this topic.
About the MRF Patient Forum

The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.